Metastatic breast cancer

Showing 9 of 0 results

• Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Machine learning
  • Metastatic breast cancer
  • Artificial intelligence
• Real-world post-progression outcomes following 1L ribociclib + aromatase inhibitor (AI) versus Al alone in African American and low socio-economic status patients with HR+/HER2- mBC in US

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Health equity
  • Metastatic breast cancer
• Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer

  Breast

  • Publication summary
  • Publications
  • Metastatic breast cancer
• Real-world overall survival with palbociclib plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer who are overweight/obese

  SABCS

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer
• Real-world progression-free survival 2 and tumor response with CDK4/6is + aromatase inhibitor in patients with HR+/HER2– metastatic breast cancer

  SABCS

  • Publication summary
  • Publications
  • Metastatic breast cancer
• Assessing bias in LLM-extracted real-world data: A health equity analysis of access to care and outcomes in metastatic breast cancer

  ISPOR Europe

  • Publication summary
  • Publications
  • Metastatic breast cancer
• Comparing countries’ time to treatment initiation: A study of metastatic breast cancer in Austria and the United States

  ISPOR Europe

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer
• Are real-world survival outcomes in metastatic breast cancer transportable between the US and Austria?

  ISPOR Europe

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer
• Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice

  ESMO Open

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Metastatic breast cancer
  • Breast cancer